Discontinued — last reported Q4 '25
Boston Scientific Asia Pacific — Net Sales remained flat by 0.0% to $770.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.7%, from $671.50M to $770.00M. Over 4 years (FY 2021 to FY 2025), Asia Pacific — Net Sales shows an upward trend with a 10.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates successful market expansion, strong demand for the company's medical device portfolio, or effective commercial execution in the region, while a decrease may signal increased competition, regulatory hurdles, or economic headwinds in these markets.
This metric represents the total revenue generated from the sale of medical devices and related services within the Asia...
Peers in the medical device industry typically report regional revenue to demonstrate geographic diversification and exposure to global healthcare spending trends.
bsx_segment_asia_pacific_net_sales| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $2.07B | $2.12B | $2.40B | $2.69B | $3.08B |
| YoY Change | — | +2.2% | +13.4% | +11.9% | +14.7% |